# Catherine Thieblemont

Source: https://onco.cc/people/catherine-thieblemont/  
OnCo record `catherine-thieblemont` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma.

## Summary

Catherine Thieblemont (Hôpital Saint-Louis, Paris) was principal investigator of EPCORE NHL-1, the pivotal trial showing the subcutaneous CD3xCD20 bispecific epcoritamab produces deep, durable responses in relapsed or refractory large B-cell lymphoma, leading to its approval. She has led LYSA trials in marginal zone and elderly DLBCL and co-chairs the EPCORE programme moving bispecifics into earlier lines.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; bispecific; lysa
- Role: Head of Hemato-Oncology, Hôpital Saint-Louis, Paris; Professor, Université Paris Cité
- Specialisms: Aggressive lymphoma; Bispecific antibodies; Marginal zone lymphoma; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD20](https://onco.cc/targets/cd20/), [CD3](https://onco.cc/targets/cd3/)
- institutions: [Cancer Institute AP-HP Nord, Université Paris Cité](https://onco.cc/institutions/aphp-nord-cancer-institute/)
- trials: [ELARA](https://onco.cc/trials/elara/), [EPCORE DLBCL-1](https://onco.cc/trials/epcore-dlbcl-1/), [EPCORE NHL-1](https://onco.cc/trials/epcore-nhl-1/), [REMARC](https://onco.cc/trials/remarc/)
- key papers: [EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T](https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/), [Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP](https://onco.cc/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/), [Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma](https://onco.cc/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/), [Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial](https://onco.cc/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/catherine-thieblemont.json